- Home
- SUPN vs HAYW Comparison
SUPN vs HAYW Comparison
Compare SUPN & HAYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SUPN | HAYW |
|---|---|---|
| Founded | 2005 | 1925 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electronic Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.1B |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SUPN | HAYW |
|---|---|---|
| Price | $45.61 | $14.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $61.60 | $17.50 |
| AVG Volume (30 Days) | 492.7K | ★ 2.2M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.93 |
| EPS | N/A | ★ 0.11 |
| Revenue | $392,755,000.00 | ★ $1,122,155,000.00 |
| Revenue This Year | $22.70 | $6.22 |
| Revenue Next Year | $19.14 | $5.96 |
| P/E Ratio | ★ N/A | $133.64 |
| Revenue Growth | N/A | ★ 6.71 |
| 52 Week Low | $31.16 | $12.93 |
| 52 Week High | $59.68 | $17.73 |
Technical Indicators
Market Signals| Indicator | SUPN | HAYW |
|---|---|---|
| Relative Strength Index (RSI) | 41.88 | 60.06 |
| Support Level | $43.67 | $14.37 |
| Resistance Level | $46.89 | $16.41 |
| Average True Range (ATR) | 1.46 | 0.35 |
| MACD | -0.17 | 0.09 |
| Stochastic Oscillator | 34.48 | 95.69 |
Price Performance
Historical ComparisonAbout SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
About HAYW Hayward Holdings Inc.
Hayward Holdings is a leading manufacturer of energy-efficient swimming pool equipment and pool automation systems. The company offers a wide range of pool equipment, including pumps, filters, heaters, LED lights, and sanitization. Headquartered in Charlotte, North Carolina, the company has around 2,000 full-time employees. Hayward generated approximately $1.1 billion in revenue in 2025.